Therapy: Rituximab has similar short-term safety and efficacy to cyclophosphamide in ANCA-associated vasculitis

Comment

. 2010 Oct;6(10):556.

doi: 10.1038/nrrheum.2010.150.

Comment

Shreeya Nanda. Nat Rev Rheumatol. 2010 Oct.

. 2010 Oct;6(10):556.

doi: 10.1038/nrrheum.2010.150.

No abstract available

Comment on

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DR; European Vasculitis Study Group. Jones RB, et al. N Engl J Med. 2010 Jul 15;363(3):211-20. doi: 10.1056/NEJMoa0909169. N Engl J Med. 2010. PMID: 20647198 Clinical Trial.
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U; RAVE-ITN Research Group. Stone JH, et al. N Engl J Med. 2010 Jul 15;363(3):221-32. doi: 10.1056/NEJMoa0909905. N Engl J Med. 2010. PMID: 20647199 Free PMC article. Clinical Trial.

The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review.
Habibi MA, Alesaeidi S, Zahedi M, Hakimi Rahmani S, Piri SM, Tavakolpour S. Habibi MA, et al. Biology (Basel). 2022 Dec 6;11(12):1767. doi: 10.3390/biology11121767. Biology (Basel). 2022. PMID: 36552276 Free PMC article. Review.